Synthesis and initial in vitro evaluation of olmutinib derivatives as prospective imaging probe for non-small cell lung cancer

Introduction: Imaging a non-small cell lung cancer (NSCLC) using radiolabeled tyrosine kinase inhibitors (TKIs) has attracted attention due to their unique interaction with the target epidermal growth factor receptor (EGFR). Olmutinib (OTB) is one of the third-generation EGFR TKIs, which selectively inhibit EGFR L858R/T790M mutation. In this study, we aim to estimate the interaction of the iodinated OTB (I-OTB)-receptor complex by molecular docking. Furthermore, we will synthesize the I-OTB and evaluate its activity toward EGFR L858R/T790M by in vitro cytotoxicity assay. Methods: A molecular docking simulation was carried out using an AutoDock Vina program package to estimate the interaction of the ligand-receptor complex. The I-OTB, N-{3-iodo-5-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]aminothieno{3,2-d}pyrimidin-4-yl)oxy]phenyl} acrylamide, was synthesized by introducing an iodine atom in the phenyl group in the 3-aryloxyanilide structure. The half inhibitory concentration (IC50) was determined by employing a 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H tetrazolium monosodium salt (WST-8) assay to evaluate the activity of I-OTB. Results: The docking study exhibited that I-OTB could take an interaction similar to that of the parent compound. We successfully synthesized I-OTB and confirmed its structure by instrumental analysis. The binding energy of OTB and I-OTB in complex with EGFR T790M are -8.7 and -7.9 kcal/mol, respectively. The cytotoxicity assay showed that I-OTB also has an affinity towards the EGFR L858R/T790M mutation with the IC50 10.49 ± 5.64 𝜇M compared to the EGFR wild type with the IC50 over than 10 𝜇M. Conclusion: The cytotoxicity effect of I-OTB was comparable to that of OTB. This result indicates that the iodine substituent in OTB did not alter the parent compound selectivity toward double mutations EGFR L858R/T790M. Therefore, I-OTB is prominent for radioiodination, and [123/124I]I-OTB may be a promising candidate for EGFR L858R/T790M mutation imaging.

[1]  J. Taki,et al.  Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib. , 2022, Journal of medicinal chemistry.

[2]  I. Kurniawan,et al.  Molecular modelling on SARS-CoV-2 papain-like protease: an integrated study with homology modelling, molecular docking, and molecular dynamics simulations , 2021, SAR and QSAR in environmental research.

[3]  I. Kurniawan,et al.  Theoretical studies of Thiazolyl-Pyrazoline derivatives as promising drugs against malaria by QSAR modelling combined with molecular docking and molecular dynamics simulation , 2021 .

[4]  R. Nishii,et al.  A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma , 2021, Pharmaceuticals.

[5]  R. Nishii,et al.  Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR) , 2020, Molecules.

[6]  A. Sutherland,et al.  Recent Advances in Synthetic Methods for Radioiodination. , 2020, The Journal of organic chemistry.

[7]  Jin Xie,et al.  Radioiodinated tyrosine based carbon dots with efficient renal clearance for single photon emission computed tomography of tumor , 2019, Nano Research.

[8]  K. Lee,et al.  A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third‐generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers , 2019, Basic & clinical pharmacology & toxicology.

[9]  Keunchil Park,et al.  Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. , 2019, Lung cancer.

[10]  K. Ogawa,et al.  Radiotheranostics Coupled between an At-211-Labeled RGD Peptide and the Corresponding Radioiodine-Labeled RGD Peptide , 2019, ACS Omega.

[11]  T. Hansen,et al.  A convenient synthesis of phenols , 2018, Synthetic Communications.

[12]  Xiaoyuan Chen,et al.  Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging , 2018, The Journal of Nuclear Medicine.

[13]  A. Tsatsakis,et al.  The use of structural alerts to avoid the toxicity of pharmaceuticals , 2018, Toxicology reports.

[14]  I. C. Kok,et al.  Molecular Imaging in Cancer Drug Development , 2018, The Journal of Nuclear Medicine.

[15]  S. Gambhir,et al.  A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management , 2018, Science Translational Medicine.

[16]  C. Yun,et al.  Structural basis of mutant-selectivity and drug-resistance related to CO-1686. , 2017, Oncotarget.

[17]  D. Gandara,et al.  Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  M. C. Feiters,et al.  Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination , 2017, European journal of organic chemistry.

[19]  Arwansyah,et al.  Molecular docking simulation of mangostin derivatives and curcuminoid on maltase- glucoamylase target for searching anti-diabetes drug candidates , 2016, 2016 1st International Conference on Biomedical Engineering (IBIOMED).

[20]  Matthew Grist,et al.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity , 2016, Clinical Cancer Research.

[21]  D. Yankelevitz,et al.  The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Esther S. Kim.  Olmutinib: First Global Approval , 2016, Drugs.

[23]  Takatoshi Ito,et al.  Hydrolysis of Diazonium Salts Using a Two-Phase System (CPME and Water) , 2015 .

[24]  M F Lythgoe,et al.  Bimodal Imaging of Inflammation with SPECT/CT and MRI Using Iodine-125 Labeled VCAM-1 Targeting Microparticle Conjugates. , 2015, Bioconjugate chemistry.

[25]  H. Manning.  World Molecular Imaging Congress 2015: Precision Medicine Visualized , 2015, Molecular Imaging and Biology.

[26]  Ji Yeon Song,et al.  Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor , 2014 .

[27]  Neeraj Kumar,et al.  Catalyst-free water mediated reduction of nitroarenes using glucose as a hydrogen source , 2013 .

[28]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[29]  V. Krasnykh,et al.  Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT , 2011, Proceedings of the National Academy of Sciences.

[30]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[31]  K. Ogawa,et al.  Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy , 2009, Cancer science.

[32]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[33]  J. Gelovani.  Molecular imaging of epidermal growth factor receptor expression–activity at the kinase level in tumors with positron emission tomography , 2008, Cancer and Metastasis Reviews.

[34]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[35]  Edward J. Fox,et al.  The Impact of Retail Location on Retailer Revenues : An Empirical Investigation January 2007 , 2007 .

[36]  J. Soria,et al.  Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  P. Blower,et al.  World Molecular Imaging Congress , 2013 .

[38]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .